2020
DOI: 10.1016/j.intimp.2020.106873
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Highlights Thymosin α1can markedly decrease 28-day mortality (HR, 0.11, 95% CI 0.02–0.63, P = 0.013) and attenuate acute lung injury ( P = 0.036) in critical type COVID-19 patients. Thymosin α1 can markedly prolonged the hospital length of stay ( P = 0.024) as well as the total duration of the disease ( P = 0.001) in the critical type CO… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
34
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 36 publications
(34 citation statements)
references
References 28 publications
0
34
0
Order By: Relevance
“…Subsequent evidence, even stronger, came from a multicenter retrospective analysis of 334 COVID-19 patients enrolled to receive thymosin α1 for 5 days or more from December 2019 to March 2020 [ 42 ]. The primary outcomes measured were the 28- and 60-day mortality; the secondary outcomes were hospital length of stay and the total duration of the disease.…”
Section: Rationale and Timing For The Potential Use Of Thymosin α1 In Cmentioning
confidence: 99%
See 1 more Smart Citation
“…Subsequent evidence, even stronger, came from a multicenter retrospective analysis of 334 COVID-19 patients enrolled to receive thymosin α1 for 5 days or more from December 2019 to March 2020 [ 42 ]. The primary outcomes measured were the 28- and 60-day mortality; the secondary outcomes were hospital length of stay and the total duration of the disease.…”
Section: Rationale and Timing For The Potential Use Of Thymosin α1 In Cmentioning
confidence: 99%
“…The 28-day mortality between the thymosin α1 and nonthymosin α1-treated groups was significantly different in adjusted model (p = 0.016). According to the subgroup analysis, thymosin α1 therapy significantly reduced 28-day mortality (hazard ratio, HR: 0.11; 95% CI: 0.02–0.63; p = 0.013) by improving Pa0 2 /FiO 2 ratio (p = 0.036) and prolonged the hospital length of stay (p = 0.024) as well as the total duration of the disease (p = 0.001) in the critical type patients (who were defined by age, blood parameters, acute physiology and chronic health evaluation) [ 42 ].…”
Section: Rationale and Timing For The Potential Use Of Thymosin α1 In Cmentioning
confidence: 99%
“…A recent study showed that Thymosin-α1 reversed Tcell exhaustion and recovered immune reconstitution through promoting thymus output, and then significantly reduced mortality in severe COVID-19 patients (7). Another study also showed that Thymosin-α1 therapy significantly reduced 28-day mortality (HR, 0.11, 95% CI 0.02-0.63, p = 0.013) in severe patients with COVID-19 (8). However, the two studies only evaluated the efficiency of Thymosin-α1 on severe patients with COVID-19.…”
Section: Introductionmentioning
confidence: 97%
“…Through the system electronic retrieval and other ways, a total of 6 studies were obtained. After screening the title, summary and full text, 1498 patients with COVID-19 were included in meta-analysis in four studies [ [7] , [8] , [9] , [10] ]. Table 1 summarizes the basic features of inclusion studies, and the individual and collective RRs analysis of the relationship between thymosin use and mortality is shown in Fig.…”
mentioning
confidence: 99%
“…COVID-19 can lead to immune system dysfunction and poor prognosis. Thymosin a1 is a peptide originally isolated from thymus tissue, which has dual mechanisms during inflammation [ 7 , 11 ]. It can repair T cells by promoting T cell maturation and inhibiting apoptosis, and prevent proinflammatory cytokine storm by increasing regulatory T cells [ [12] , [13] , [14] ].…”
mentioning
confidence: 99%